MENLO PARK, Calif.,
June 22, 2017
/PRNewswire/-- BioPharmX Corporation (NYSE MKT: BPMX),
a specialty pharmaceutical company focusing on dermatology, will
present results of its phase 2b of BPX-01, a unique topical
hydrophilic gel formulation of minocycline, at the Alabama
Dermatology Society's Summer Symposium being held June 22-25 in Sandestin, Fla.
Findings from the phase 2b will be discussed during the
presentation "Acne Vulgaris: What Do Available and Newer
Therapies Bring to the Table?" by Dr. James Q. Del Rosso, founder of JDR Dermatology
Research, Las Vegas. His presentation is scheduled for
10 a.m. Friday.
The company's poster presentation, entitled "Results from a
Randomized, Double-Blind, Vehicle-Control Study to Assess the
Safety and Efficacy of BPX-01 Minocycline Topical Gel in the
Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris,"
will take place at 7:00 p.m. CDT
today.
Phase 2b data showed the 2% formulation of BPX-01 reduced acne
lesions in subjects by 59% (compared to 44% for vehicle) and
delivered at least a two-grade reduction in investigator global
assessment (IGA) and clear to almost clear for 25% of
subjects. The Phase 2b research was not powered to measure
IGA statistical significance. The study found BPX-01 was
generally well tolerated, without any serious drug-related adverse
events experienced, no photosensitivity, staining or skin
discoloration.
While BioPharmX previously presented phase 2b data to the
investor community, the Symposium will be the first time it shares
the research in a medical conference. It will also be the first
time the medical community hears research showing that subjects had
a positive experience with BPX-01. A survey of subjects at
week 12 found that 79% thought BPX-01 2% was easy to use and
apply. 86% said they would use BPX-01 2% again.
"Efficacy and safety are crucial to dermatologists and their
acne patients, but just as important is patient compliance," said
G. Scott Herron, M.D., Ph.D.,
BioPharmX Medical Director, board-certified dermatologist and
fellow of the American Academy of Dermatology. "Medicines
that are easy to use improve compliance. Phase 2b subjects
told us BPX-01 is easy to use and they expressed a willingness to
use it again. We believe this gives BPX-01 a significant advantage
over topical therapies that have irritating side effects like
rashes, dryness or itching, or oral therapies that are associated
with headaches, dizziness or diarrhea."
BPX-01 is the first topical gel formulation of minocycline that
can penetrate the skin to deliver the antibiotic to the
pilosebaceous unit, where acne develops. It is also the first and
only stable hydrophilic and non-oil-based topical gel with fully
solubilized minocycline. The company's studies are designed to
confirm whether BPX-01 will effectively treat acne with lower
dosages of the antibiotic with no or fewer adverse side
effects.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting up to 50 million
Americans. The disease can cause permanent scarring, low
self-esteem, depression and anxiety.
About BioPharmX® Corporation
BioPharmX
Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty
pharmaceutical company, which seeks to provide products through
proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, which are subject to the "safe harbor" created by
those sections. This press release contains forward-looking
statements about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding the
safety and medical effects of BPX-01, the effect BPX-01 may have on
the treatment of acne, the commencement and results of future
trials of BPX-01 and the size of such trials, continued and
consistent results in future tests of BPX-01 and absence of side
effects of future use of BPX-01. These forward-looking statements
may be identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such
forward-looking statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017 and our quarterly report on Form 10-Q for
the period ended April 30, 2017.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof, and the company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
law.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-to-present-phase-2b-clinical-trial-acne-data-at-alabama-dermatology-society-summer-symposium-300477958.html
SOURCE BioPharmX Corporation